PSMA PET/CT to evaluate response to SBRT for prostate cancer bone metastases.

Background: In the current study we evaluated Ga PSMA PET/ CT to measure local control of bone metastasis in oligometastatic prostate cancer patients treated with SBRT.

Materials And Methods: After the institutional review board approval, a retrospective review of medical records of consecutive prostate cancer patients treated between 2014 and 2018 was conducted. Only medical records of patients that were treated with SBRT for bone metastasis and had pre-and post-SBRT Ga PSMA PET/CT scans were included in our study.